Bispecific antibody platforms for cancer immunotherapy

R. Lameris; Renee de Bruin; F.L. Schneiders; P van Bergen en Henegouwen; H.M. Verheul; T.D. de Gruijl; H.J. van der Vliet

doi:10.1016/j.critrevonc.2014.08.003

Bispecific antibody platforms for cancer immunotherapy

R. Lameris, Renee de Bruin, F.L. Schneiders, P van Bergen en Henegouwen, H.M. Verheul, T.D. de Gruijl, H.J. van der Vliet

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

165AbstractOver the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novelbispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinicalstudies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that wereencountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.

Original language	English
Pages (from-to)	153-165
Journal	Critical Reviews in Oncology Hematology
Volume	92
DOIs	https://doi.org/10.1016/j.critrevonc.2014.08.003
Publication status	Published - 2014

Keywords

Bi-specific antibodies
Dual specific retargeting
Immune effector cells
Anti-cancer therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2014.08.003

Embargoed Document

bispecific
Final published version, 1.54 MB
Embargo ends: 1/01/50
Request copy

Cite this

@article{14f29c988cac4490b97178b6dbc0312f,

title = "Bispecific antibody platforms for cancer immunotherapy",

abstract = "165AbstractOver the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novelbispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinicalstudies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that wereencountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.",

keywords = "Bi-specific antibodies, Dual specific retargeting, Immune effector cells, Anti-cancer therapy",

author = "R. Lameris and {de Bruin}, Renee and F.L. Schneiders and {van Bergen en Henegouwen}, P and H.M. Verheul and {de Gruijl}, T.D. and {van der Vliet}, H.J.",

year = "2014",

doi = "10.1016/j.critrevonc.2014.08.003",

language = "English",

volume = "92",

pages = "153--165",

journal = "Critical Reviews in Oncology Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd.",

}

TY - JOUR

T1 - Bispecific antibody platforms for cancer immunotherapy

AU - Lameris, R.

AU - de Bruin, Renee

AU - Schneiders, F.L.

AU - van Bergen en Henegouwen, P

AU - Verheul, H.M.

AU - de Gruijl, T.D.

AU - van der Vliet, H.J.

PY - 2014

Y1 - 2014

N2 - 165AbstractOver the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novelbispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinicalstudies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that wereencountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.

AB - 165AbstractOver the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novelbispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinicalstudies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that wereencountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.

KW - Bi-specific antibodies

KW - Dual specific retargeting

KW - Immune effector cells

KW - Anti-cancer therapy

U2 - 10.1016/j.critrevonc.2014.08.003

DO - 10.1016/j.critrevonc.2014.08.003

M3 - Article

SN - 1040-8428

VL - 92

SP - 153

EP - 165

JO - Critical Reviews in Oncology Hematology

JF - Critical Reviews in Oncology Hematology

ER -

Bispecific antibody platforms for cancer immunotherapy

Abstract

Keywords

UN SDGs

Access to Document

Embargoed Document

Fingerprint

Cite this